Search Results
Found 36 results for "oncology" across articles, medicines, trials, companies and the glossary
Clinical trials in IrelandTracker →
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax…Active · Loxo Oncology, Inc.
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab…Active · Loxo Oncology, Inc.
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refr…Recruiting · Princess Maxima Center for Pediatric Oncology
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating …Active · NRG Oncology
Industry
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
A comprehensive guide to utilizing Priya Life Science's live trackers. Learn how to track clinical trials, regulatory recalls, drug shortages, biotech layoffs, and M&A venture activity to accelerate your career and optimize market intelligence.
Industry
Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
An in-depth analysis of Ireland's €93.8 billion pharmaceutical and medical exports to non-EU markets. Examining trade data across the United States, UK, Switzerland, and Asia-Pacific, key manufacturing clusters in Cork, Dublin, and Limerick, and the strategic outlook for 2026.
Industry
Women in Pharma Awards 2026 Recognise Sector’s Outstanding Talent Across Ireland
20 trophies presented at gala Dublin ceremony celebrating leadership, innovation, and clinical trials excellence across Ireland's €100B+ pharmaceutical and life sciences sector.
Industry
Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines
Global equity markets open August 2026 on a historic high as rumored $400B AstraZeneca-BMS merger talks and Curium's $8B Lantheus acquisition spark a massive biopharmaceutical consolidation wave.
Industry
AI in Pharma H1 2026 Report: Mega-Deals, On-Premise Supercomputer Factories, and Clinical Translation Milestones
A comprehensive half-year update on artificial intelligence in pharmaceutical drug discovery, detailing Isomorphic's $2.1B Series B, Insilico's multi-billion partnerships, NVIDIA's private AI factories, and Phase I/II clinical pipeline progress.
Industry
US Pharmaceutical Tariffs Update: Policy Realities, The Stockpile 'Unwind', and Ireland’s Strategic Position
An in-depth analysis of where US pharmaceutical tariff policies stand in mid-2026 under the Trump administration, analyzing recent CSO export data, inventory stockpiling corrections, MFN agreements, and Ireland’s strategic biopharma position.
Industry
High Expectations, Historic Opportunity: What Ireland’s Rotating EU Council Presidency Can Deliver for European and Irish Pharma
A Priya Life Science White Paper analyzing the pivotal policy dossiers of the 2026 Irish Presidency, the economic stakes for biopharma manufacturing, and key strategic recommendations.
Regulatory Affairs
The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories
An in-depth commercial analysis of the UK-India Comprehensive Economic and Trade Agreement (CETA), exploring its transformative impact on bilateral pharmaceutical manufacturing, active pharmaceutical ingredient (API) supply chains, and consumer medicine pricing.
Regulatory Affairs
Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots
The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines - a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.
Regulatory Affairs
Therapeutic Hotspots of 2026: Evolving Pipelines in Antibody-Drug Conjugates (ADCs) and GLP-1 Obesity Platforms
Global research pipelines and venture capital inflows are concentrating in targeted cancer therapy with ADCs and next-generation cardiometabolic GLP-1 oral weight-loss compounds.
Clinical Trials
ASCO 2026 Highlights: Landmark Clinical Data Points to Survival Extensions in Pancreatic and Lung Cancers
The annual ASCO conference has delivered landmark clinical trial results, bringing promising survival extensions for pancreatic cancer and targeted lung cancer therapies.
Industry
Global Biopharma M&A Rebounds in 2026: AbbVie and Merck KGaA Lead Multi-Billion Dollar Acquisitions
Global pharmaceutical dealmaking has surged in 2026 as cash-rich majors AbbVie and Merck KGaA close multi-billion dollar acquisitions to restock pipelines ahead of late-decade patent cliffs.
LinkedIn
LinkedIn PR for Life Science & Pharma: The Definitive Guide to Building Credibility, Authority, and Visibility in 2026
A practitioner-level guide to building genuine professional authority on LinkedIn as a pharmaceutical, biotech, or MedTech professional. Covers profile architecture, content strategy, engagement tactics, thought leadership frameworks, and the exact playbooks used by the most followed life science voices on the platform.
Biotechnology
From Farming to Pharma: The History of Ireland’s Life Sciences Revolution
How did a nation once defined by agriculture and emigration transform into the world’s third-largest exporter of pharmaceuticals? We trace the deliberate policy shifts, educational reforms, and FDI strategies that built Ireland’s booming life sciences ecosystem.
Clinical Trials
Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment
Helus Pharma announces a $50 million offering to progress Phase 3 trials for their novel serotonergic agonists, alongside major clinical milestones and leadership updates.
Biotechnology
A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge
An in-depth analysis of the massive wave of pharmaceutical mergers and acquisitions in the first half of 2026, driven by patent cliffs, pipeline replenishment, and high-growth therapeutic areas.
Pharmaceutical
The Innovation Exodus: Why Europe Must Rethink Medicine Pricing or Risk Losing Life Science Investments
An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.
Pharmaceutical
Scaling Ireland’s Biopharma Leadership: Inside Eli Lilly’s $2.8 Billion Manufacturing Expansion in Limerick and Kinsale
An in-depth analysis of Eli Lilly’s massive manufacturing footprint in Limerick and Kinsale, highlighting local jobs, high-tech biologic drug production, and Ireland’s strategic position in the global biopharma supply chain.
LinkedIn
LinkedIn for Medical Science Liaisons (MSLs): The Complete Guide to Showcasing Scientific Expertise Without Violating Compliance
A step-by-step compliance-safe LinkedIn guide exclusively for Medical Science Liaisons. Covers profile optimisation, what to post, what never to post, KOL engagement, off-label rules, digital medical affairs strategy, and how to build scientific credibility on LinkedIn without breaching pharmaceutical regulatory guidelines.
LinkedIn
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.
Biotechnology
Global Biopharma Layoff Tracker Report (2025-2026): A Structural Reshaping
A detailed global report analyzing major pharmaceutical and biotech layoffs across the US, EU, and India from 2025 to 2026, including strategic shifts by enGene, Takeda, Bayer, and BioNTech.
Biotechnology
Global Pharma Giants Pledge $500 Billion in U.S. Investments
Drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively announced approximately $500 billion in U.S. investments aimed at strengthening infrastructure and reducing supply-chain vulnerabilities.
Pharmaceutical
Eisai Allocates £48M to UK Cold-Chain Pharma Packaging Hub
Japanese pharmaceutical company Eisai announces a £48 million investment at its Hatfield, UK site to establish advanced cold-chain supply and packaging capabilities, supported by the Life Sciences Innovative Manufacturing Fund.
Clinical Trials
J-Pharma and Uniphar Advance Nanvuranlat into Global Phase III Trial for Biliary Tract Cancer
Japanese biotech J-Pharma and Ireland-based Uniphar have received FDA alignment to bypass Phase II and advance nanvuranlat (JPH203) directly into a pivotal global Phase III study for second-line biliary tract cancer.
Industry
Jazz Pharmaceuticals Strikes Strategic $820M Research Deal with AbCellera for Next-Gen T-Cell Engaging Antibodies
Discover how Jazz Pharmaceuticals and AbCellera are joining forces in a high-stakes, $820M biopharma collaboration to pioneer next-generation T-cell engaging (TCE) multispecific antibodies targeting gastrointestinal cancers and challenging solid tumors.
Pharmaceutical
Leading CDMO Companies in Ireland: Your Complete Guide to Contract Manufacturing in 2026
A comprehensive guide to the top CDMO companies in Ireland - from Hovione and Thermo Fisher in Cork to EirGen Pharma in Waterford and HiTech Health in Galway. Full profiles, capabilities, certifications, and facilities of Ireland's leading contract development and manufacturing organizations.
Clinical Trials
Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback
In the rigorous and highly demanding landscape of oncology research, scientific progress is often non-linear. Recently, Jazz Pharmaceuticals and its partner PharmaMar announced that their Phase 3 trial evaluating Zepzelca did not meet its primary endpoint.
MedTech
Emerging Pharma Companies in Ireland to Watch in 2026
Discover the top 5 high-growth Irish life science, biotech, and medtech companies transforming the healthcare landscape. From Enterprise Ireland backed startups to global scale-ups, these are the emerging leaders of 2026.
LinkedIn
A Systematic LinkedIn Strategy for Small Pharma and Biotech Firms
A structured, step-by-step report on how small and emerging life science firms can leverage LinkedIn to build corporate reputation, increase brand awareness, and attract investors without massive marketing budgets.
Industry
10 Companies Actively Recruiting for Future Health Roles in Ireland - 2026 Hiring Guide
From AI-powered diagnostics to digital therapeutics and connected devices - these 10 companies are reshaping healthcare in Ireland and hiring right now. Here's where the future health jobs are and how to land one.
Industry
Why Eli Lilly's €2 Billion Bet on Limerick is a Career Game-Changer for Irish Pharma
Eli Lilly has committed over €2 billion to its Raheen biomanufacturing campus - the largest single pharma investment in Irish history. Here's what it means for your career in 2026.